[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ventricular-arrhythmias\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ventricular-arrhythmias":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,51,85,117,148,174],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":31,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100621718","do-qt-prolonging-drugs-cause-major-adverse-cardiac-events-in-hospitalized-adults-100621718",false,"NCT07374263","Do QT-Prolonging Drugs Cause Major Adverse Cardiac Events in Hospitalized Adults?","Do 'Known' QT-prolonging Medications Cause Major Adverse Cardiac Events in Hospitalized Adults? The QTP-MACE Study","QTP-MACE","Inclusion Criteria:\n\n* Adult patients 18 years of age or older\n* Admitted to St. Joseph's Healthcare Hamilton or GEMINI hospitals between December 2017 and March 2025\n\nExclusion Criteria:\n\n* Patients \\\u003C18 years old\n* Outpatient encounters","ALL","18 Years",{"count":20,"type":21},990000,"ESTIMATED","OBSERVATIONAL","There are 28 non-cardiology medications from multiple families costing more than $13 billion annually in Canada, categorized as 'Known' QT-prolonging medications (QTPmeds) based on very low levels of evidence. The association between many commonly used medications listed as known QTPmeds and actual major adverse cardiac events (MACE) is weak. Meanwhile, QTPmeds-related warnings are ubiquitous in every healthcare setting, triggering 'hard stop' disruption millions of times per day to front line clinicians. Poor quality medication safety alerts are increasingly recognized as a source of inferior patient care and provider burnout which detracts from healthcare sustainability.\n\nIn this study, anonymized hospital electronic medical record data from more than 990,000 adult patients across Ontario will be used to compare patients who experience MACE with those who do not, measuring their real-time exposure to QT-prolonging drugs. Additionally, machine-learning techniques will also be used to find which patient or treatment factors best predict risk.\n\nThe objectives of this study are to 1) Investigate whether exposure to one or more 'Known' QTPmed is associated with an increased risk of MACE after adjusting for confounders; and 2) Identify predictors and their relative importance for QTPmeds-associated MACE.\n\nIn summary, QT-prolonging medications have the potential to cause very serious adverse events, including death. However, it is not sufficiently clear which patients under which circumstances suffer events, or when is QT prolongation a useful surrogate marker for harm. Meanwhile, ubiquitous medication alerts related to QT-prolonging medications are at best imprecise and at worst, misleading, costly and potentially dangerous. Now that data resources are available with the data elements, structure and sample size required to rigorously assess this association, this study will address this question to improve patient safety, provider satisfaction and the cost-effectiveness of care.",[25,26,27,28,29,30],"Acquired Long QT","Ventricular Arrhythmias","Torsades de Pointes","Syncope","Medication Safety","MACE",[32,33,34,35,36,37],"Medication safety","QT interval prolongation","Long QT syndrome","Ventricular arrhythmia","Torsades de pointes","Major adverse cardiac events","RECRUITING","2026-01-24",{"date":41,"type":42},"2026-01-28","ACTUAL",{"date":44,"type":42},"2025-02-01",{"date":46,"type":21},"2027-12",{"name":48,"class":49},"St. Joseph's Healthcare Hamilton","OTHER",2,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":68,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":84},"100537757","phase-3-study-evaluating-dexmedetomidine-in-the-acute-treatment-of-electrical-storm-100537757","NCT06281977","Study Evaluating Dexmedetomidine in the Acute Treatment of Electrical Storm","SEDATE","Inclusion Criteria:\n\n\\- All patients admitted to an intensive care unit with electrical storm over the age of 18 years will be approached for enrollment.\n\nExclusion Criteria:\n\n* Refractory shock lasting for more than 30 minutes unrelated to ventricular arrhythmias (VAs), defined as requiring two or more vasopressors\n* SCAI class D or E cardiogenic shock\n* Cardiac arrest(s) with a no-flow and low-flow total time of greater than 10 minutes prior to recruitment.\n* ST-segment elevation myocardial infarction (STEMI)-induced VA with signs of active ischemia.\n* Bradycardia with heart rate less than 40 beats per minute, bradycardia-induced ventricular tachyarrhythmia, second degree Mobitz type 2 or greater atrioventricular block in the absence of a pacemaker.\n* Pregnancy\n* Known dexmedetomidine allergy or intolerance\n* Inability to obtain consent from patient or substitute decision maker.\n* Patients who have received dexmedetomidine or clonidine during the 24 hours prior to randomization",{"count":59,"type":21},192,"INTERVENTIONAL",[62],"PHASE3","The objective of this study is to determine if there is a meaningful benefit to using the sedative medication dexmedetomidine in the acute treatment of patients with recurrent ventricular arrhythmias, known as electrical storm. This will be a multi-centre, double-blinded, placebo-controlled, randomized trial. Patients with electrical storm will be randomized to receive 48 to 72 hours of dexmedetomidine or placebo as part of their initial treatment in an intensive care unit.",[65,26,66,67],"Ventricular Tachycardia","Ventricular Fibrillation","Recurrent Ventricular Tachycardia",[69,70,71,72,73,67,74],"Electrical Storm","Dexmedetomidine","Ventricular Electrical Storm","Precedex","Recurrent Ventricular Arrhythmias","Sedation","2025-12-16",{"date":77,"type":42},"2025-12-17",{"date":79,"type":42},"2024-05-08",{"date":81,"type":21},"2027-08-01",{"name":83,"class":49},"Ottawa Heart Institute Research Corporation",1,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":17,"minAge":92,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":60,"phases":95,"briefSummary":97,"conditions":98,"keywords":101,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":116},"100600918","primary-ancillary-substudy-100600918","NCT07103733","PRIMARY Ancillary Substudy","Percutaneous or Surgical Repair In Mitral Prolapse And Regurgitation for ≥60 Year-olds (PRIMARY) Ancillary Substudy","Inclusion Criteria:\n\n* Patients who meet all eligibility criteria and are randomized in the parent PRIMARY trial.\n* For the ancillary biospecimen study, patients who are randomized to MVr in the parent trial.\n\nExclusion Criteria:\n\n* Severe claustrophobia not controlled with sedation.\n* Prior adverse reaction to gadolinium administration.\n* Patients with an implantable subcutaneous cardioverter defibrillator and\u002For cardiac resynchronization therapy device with defibrillator may be excluded as they typically produce substantial artifacts on cardiac MRI making assessment very challenging.\n* Known allergic reaction to adhesives or hydrogels or with family history of adhesive skin allergies (for patients undergoing rhythm monitoring).","60 Years",{"count":94,"type":21},250,[96],"NA","The PRIMARY trial (NCT05051033), which compares mitral valve repair (MVr) to transcatheter-edge-to-edge-repair (TEER), offers a platform for conducting mechanistic studies to develop early insights into the pathophysiological processes by which mitral valve prolapse (MVP) can impact left ventricular (LV) myocardial structure and function, and, thereby, predispose to arrhythmias and sudden death. Such insights are key to identifying interventions to reduce the long-term sequelae of heart failure (HF) and arrhythmias, as well as delineate optimal therapeutic approaches for different patient sub-groups.",[99,100,26],"Mitral Valve Prolapse","Left Ventricular Fibrosis",[102,103,104,105,106],"Mitral valve repair (MVr)","Transcatheter-edge-to-edge-repair (TEER)","Cardiac magnetic resonance imaging (CMR)","ZioPatch monitoring","Heart biopsy","2025-08-14",{"date":109,"type":42},"2025-08-19",{"date":111,"type":42},"2023-10-16",{"date":113,"type":21},"2027-06-30",{"name":115,"class":49},"Annetine Gelijns",25,{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":123,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":60,"phases":127,"briefSummary":128,"conditions":129,"keywords":132,"overallStatus":138,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":84},"100594995","transcutaneous-vagus-nerve-stimulation-for-ventricular-arrhythmias-100594995","NCT07026695","Transcutaneous Vagus Nerve Stimulation for Ventricular Arrhythmias","Transcutaneous Electrical Vagus Nerve Stimulation for Suppression of Ventricular Arrhythmias","TREAT-VT","PVC Cohort\n\nInclusion Criteria:\n\n* Age \\> 18 years old.\n* Participants must understand and be willing to sign a written informed consent document.\n* PVC burden of \\>10% in a 24-hour period on Holter monitoring.\n\nExclusion Criteria:\n\n* Coronary artery disease\n* Known cardiac disease (heart failure or cardiomyopathy) in the documented absence of PVCs. Individuals with suspected PVC-induced cardiomyopathy heart failure, defined as cardiomyopathy or heart failure only diagnosed in the setting of a \\>10% PVC burden, will be allowed to participate.\n* A known diagnosis of Epilepsy.\n* Ongoing pregnancy or intention to become pregnant in the forthcoming 12 months.\n* Participants using a TENS device for any indication\n\nVT cohort\n\nInclusion Criteria:\n\n* Participants with structural heart disease and a transvenous implantable cardioverter defibrillator (ICD) in situ\n* At least three clinically significant VT events (VT events defined as either \\>30 seconds of sustained VT, appropriate ICD ATP therapies or appropriate ICD shocks) in the six months before enrolment\n\nExclusion Criteria:\n\n* Heart failure syndrome with inotrope dependency or requiring mechanical assistance.\n* Reversible cause of arrhythmia (e.g. culprit electrolyte abnormality or toxin)\n* NYHA (New York Heart Association) stage IV heart failure\n* Myocardial infarction or cardiac surgery in the last six months\n* Life expectancy \\\u003C12 months\n* Ongoing pregnancy or intention to become pregnant in the forthcoming 12 months.\n* Participants using a TENS device for any indication",{"count":126,"type":21},72,[96],"Ventricular arrhythmias are abnormal heart rhythms that arise from the bottom chambers of the heart. They can cause debilitating symptoms when they occur intermittently (these are called premature ventricular ectopics or PVCs) and can be life-threatening when they occur continuously (called ventricular tachycardia or VT). These are the most common causes of sudden cardiac death, especially in patients with pre-existing heart disease.\n\nThey can be a result of overactivation of the sympathetic nervous system, and in extreme circumstances, surgery to cut the nerve may be needed. A novel approach to target this nervous system using a transcutaneous electrical nerve stimulator (TENS) machine has successfully treated arrhythmias that come from the top chambers of the heart (atrial fibrillation). An ear clip is applied for an hour per day connected to a device (smaller than a phone) that can activate the parasympathetic nervous system (that counteracts the sympathetic nervous system). This is called Low-Level Tragus Stimulation (LLTS). Because it has been used for epilepsy for decades, we have evidence of a very high safety profile and tolerability. We plan to enrol 72 patients, 34 with many PVCs and 38 with VT, and randomise them to either first receive LLTS or first receive sham treatment (this will appear the same to the patient and researchers but without any meaningful vibrations being emitted in the sham group). Each patient will then swap over to the other treatment. We will compare whether the LLTS reduces the amount of ventricular arrhythmias during compared to the amount during the sham treatment period. We will use Holter monitors to measure the amount of PVCs after each period in the PVC group. VT patients have an implantable defibrillator that continuously monitors for VT episodes in this group. We will only enrol adults who can give informed consent, and study participation will not interfere with a patient's clinical treatment.",[130,131,26],"Premature Ventricular Complexes","Ventricular Tachycardia (VT)",[133,134,135,136,137],"double-blinded","randomized","sham-controlled","crossover","prospective","NOT_YET_RECRUITING","2025-06-18",{"date":141,"type":42},"2025-06-24",{"date":143,"type":21},"2025-06-15",{"date":145,"type":21},"2027-12-31",{"name":147,"class":49},"University College, London",{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":152,"acronym":153,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":17,"minAge":155,"maxAge":4,"enrollmentInfo":156,"targetDuration":4,"studyType":60,"phases":158,"briefSummary":159,"conditions":160,"keywords":161,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":173},"100433236","evaluation-of-electrocardiographic-measurements-by-high-density-electrode-ecg-100433236","NCT04921501","Evaluation of Electrocardiographic Measurements by High Density Electrode ECG","ECG-HD","Inclusion Criteria:\n\n* Patient managed at the Bordeaux University Hospital for assessment of documented severe ventricular arrhythmia (VF, sudden resuscitated death) or suspected (syncope, family history of sudden death, ECG or Holter abnormality) or impaired ventricular conduction, OR\n* Patients managed for prophylactic ventricular defibrillator implantation, according to international recommendations: Heart disease with ejection fraction \\\u003C 35%, heart disease with sustained ventricular tachycardia, cardiomyopathies with high rhythmic risk,\n* Women of childbearing age with effective contraception.\n\nExclusion Criteria:\n\n* patients under 14 years old,\n* pregnant or nursing woman.","14 Years",{"count":157,"type":21},1800,[96],"Cardiac electrical activity is detected on the body surface with conventional electrocardiography involving 12 leads (ECG 12). A limitation of the current ECG technique is that recordings are obtained from only 6 independent precordial leads pairs ; which may miss cardiac potentials from spatially limited regions. More extensive sampling of the body surface may contribute to additional clinical information. The present study investigates the additional sensitivity of ECG using 128 body surface leads (High Density (HD) ECG) in measuring global or regional cardiac activity.",[26],[162,163],"Signal Averaging ECG","Cardiac electrophysiology","2024-12-19",{"date":166,"type":42},"2024-12-24",{"date":168,"type":42},"2021-04-06",{"date":170,"type":21},"2027-04",{"name":172,"class":49},"University Hospital, Bordeaux",11,{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":181,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":183,"conditions":184,"keywords":187,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":5},"100562397","hybrid-score-to-predict-otva-soo-in-patients-with-wide-basal-qrs-100562397","NCT06602635","Hybrid Score to Predict OTVA-SOO in Patients with Wide Basal QRS","A Hybrid Score to Predict the Origin of Outflow Tract Ventricular Arrhythmias in Patients with Intraventricular Conduction Disorders or Paced Rhythm","Inclusion Criteria:\n\n* ventricular arrhythmia with a morphology indicating an outflow tract origin and a wide basal QRS complex\n* a QRS width greater than 110 ms was considered wide\n* willing and capable of providing written informed consent to the study\n\nExclusion Criteria:\n\n* catether ablation procedure was unsuccessful\n* infrequent arrhythmia requiring ablation guided by pacemapping.",{"count":182,"type":21},100,"Outflow tract ventricular arrhythmia (OTVA) is the most common type of ventricular arrhythmia, and catheter ablation (CA) is the primary treatment option for patients experiencing symptoms. Accurately identifying the origin site of OTVA is essential for effective catheter ablation, minimizing procedural risks, and enhancing treatment success. However, most studies that developed algorithms or scoring systems for distinguishing OTVA origins excluded participants with structural heart disease and those with paced rhythms from their study groups. A recent prospective evaluation of a hybrid score (HS) that integrates both clinical and ECG data to predict OTVA-SOO, including patients with cardiac implantable electronic devices and those with structural heart disease in our study.\n\nThe presented study aimed to assess the effectiveness of the previously described hybrid algorithm in predicting OTVA-SOO in a patient population characterized by a wide basal QRS due to intraventricular conduction defects or paced rhythms.\n\nThe Hybrid Score The Hybrid Score (HS), involves a sum of points based on clinical and ECG characteristics. Points are assigned as follows: one point each for being over 50 years old, male, and having arterial hypertension. ECG-based points are allocated according to QRS transition: 3 points for a transition in V1, 2 points for V2, 1 point for V3 if the R-wave in V3 is greater than 1 mV; 1 point is subtracted if V3 has an R-wave less than 1 mV, and further deductions or additions apply for transitions up to V6. A score ≤ 1 suggests an RVOT origin, whereas ≥ 2 suggests an LVOT origin.\n\nECGs were recorded with a standard configuration at a 25 mm\u002Fs sweep speed.\n\nPremature Ventricular Contraction (PVC) Ablation Activation mapping of spontaneous OTVAs was conducted. The procedure aimed to abolish spontaneous OTVAs, with the site of ablation marking the site of origin (SOO).\n\nCollected data\n\n* Patient Information and Consent (procedure must be done within 60 days of consent)\n* Demographics (age, gender, etc.)\n* Vital signs (length, weight, etc.)\n* Medical history, including cardiovascular risk factors, cardiomyopathy and drugs\n* ECG data\n* Echocardiographic data (left ventricular ejection fraction and left ventricular end-diastolic diameter)\n* Procedure data (number of radiofrequency applications, site of effective ablation, total radiofrequency time, total fluoro time, points mapping, procedure time)\n* Adverse Events",[185,26,186],"ECG","Catheter Ablation",[188,189,190,191],"Ventricular extrasystole","Premature ventricular complex","ecg","outflow tract ventricular arrhythmias","2024-09-21",{"date":194,"type":42},"2024-09-24",{"date":196,"type":42},"2022-01-04",{"date":198,"type":21},"2024-10-23",{"name":200,"class":49},"Centro Medico Teknon"]